Oxaliplatin Market 2019: Association between Major Key Vendors Like Sanofi to Produce Promising Growth Opportunities in Upcoming Years, says Straits Research

Oxaliplatin Market

The global oxaliplatin market is expected to reach USD 548.6 million in 2028 from USD 981.99 million in 2018 at a negative CAGR of 5.7% during the forecast period 2019–2026. Oxaliplatin, an antineoplastic chemotherapy drug, is used to treat metastatic colorectal cancer. The drugs is administered in combination with fluorouracil and leucovorin.

It segregates useful and relevant market information as per the business needs of players. Readers are provided with validated and revalidated market forecast figures such as CAGR, Heavy Load Moving Skates market revenue, production, consumption, and market share. Our accurate market data equips players to plan powerful strategies ahead of time. The Oxaliplatin report offers a deep geographical analysis where key regional and country-level markets are brought to light. The vendor landscape is also analyzed in-depth to reveal current and future market challenges and Oxaliplatin business tactics adopted by leading companies to tackle them.

The parent market for oxaliplatin, i.e., colorectal cancer treatment market, is also declining as the number of screening programs for early disease diagnosis are rising globally. With this, if the disease is diagnosed at stage I or II, the tumors are removed by the surgery. Chemotherapy is preferred at the stage III and stage IV, owing to which, the scope of the treatment therapy is limited. Declining market can also be attributed to the growing preference for other therapies and rising number of new molecules under clinical studies. The effectiveness of the molecules currently under development, are found to exhibit potent results, compared to oxaliplatin. The side effects of the alternative therapies are also comparatively less. However, ongoing scenario might change in future, if oxaliplatin gets approval for other indications.

The drug experienced introductory phase post its approval during 2002 – 2003, after which it was in the growth phase, during 2004 to 2009. In 2009, the market reached maturity, and was severely hit by the competition from generic drugs and other substitute therapies, resulting in the decline in the market size. Being in the declining phase, the market is expected to record a negative CAGR of -5.7% over the forecast period.

Obtain Brochure For Latest Technology Advancements @ 
https://straitsresearch.com/report/oxaliplatin-market/request-sample

The Major Prominent Players Covered in this Report:
Sanofi, Pfizer, Yakult Honsha, and Dr. Reddy’s laboratory, & More.

By Type, Lyophilized Powder, Aqueous Solutions
By Application, Adjuvant Treatment of Stage III Colon Cancer, Treatment of Stage IV Colorectal Cancer, Other Applications
By End Users, Hospitals and Clinics, Research Institutes, Other End Users

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of Steerable Medical Devices in these regions, from 2019 to 2026, covering:
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

View this report with a detailed description and TOC @ 
https://straitsresearch.com/report/oxaliplatin-market/toc

Our Report Covers:
Historical inferences, findings & analysis of the market from 2013 to 2018
Projections and performance forecast analysis for the future from 2019 to 2028
Production and consumption point of view (POV) analysis
Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects

Key Questions Answered in The Report:
What will the Oxaliplatin market growth rate?
What are the key factors driving the global Oxaliplatin market?
Who are the key manufacturers in the Oxaliplatin market space?
What are the market opportunities, market risk, and market overview of the Oxaliplatin market?
What are sales, revenue, and price analysis of top manufacturers of the Oxaliplatin market?
Who are the distributors, traders, and dealers of the Oxaliplatin market?
What are the market opportunities and threats faced by the vendors in the global Steerable Medical Devices Industry?
What are sales, revenue, and price analysis by types and applications of the Oxaliplatin Industry?
What are sales, revenue, and price analysis by regions of Oxaliplatin industry?
What are the driving factors contributing to market growth during the short, medium, and long term?

Key Findings:
The introduction of generics and the emergence of alternative therapies has resulted in the decline of the market size

The preference for alternative therapies is increasing at a rapid rate owing to the better efficiency and fewer side effects as compared to oxaliplatin

Rising screening programs for colorectal cancer has improved the diagnosis at earlier stages, wherein, the tumor is removed surgically, which reduces the chances of chemotherapy to treat the colorectal cancer

The market dynamics might change in the future, if the approvals for other disease indications rises significantly

In terms of the product type, lyophilized powder segment accounted for 53.9% in 2018 and it was valued at USD 529.62 million

In the current scenario, the adoption of oxaliplatin to treat metastatic cancer is the highest in North America, owing to which it holds the largest share with 43.7%. The North America oxaliplatin market was valued at USD 428.9 million in 2018 and expected to reach 223.8 million by 2028, at a negative CAGR of -6.3%

The rate of market decline will be lowest in the developing economies as the adoption of substitute therapies is the lowest in these regions. Moreover, the awareness of colorectal cancer screening programs is also less. At stage III or stage IV, the preferred treatment to treat colorectal cancer is chemotherapy. Thus, the market is declining at comparatively slow rates in the developing economies

Asia Pacific was valued at 192.9 million in 2018 and expected to reach USD 126.7, at a negative CAGR of -4.2%

Browse Full Report @ 
https://straitsresearch.com/report/oxaliplatin-market

Even if your business is a multinational venture or a single storefront, we believe innovation is the key to progress, in both what you build and how you promote your products and brands.

Buy Full Report with Detail Analysis with COVID-19 Impact – https://straitsresearch.com/buy-now/oxaliplatin-market/global/

So let's put our minds together. We'll make your vision a reality and help you grow.

For more details, please contact us -
Straits Research
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY 10022
Tel: +1 646 480 7505, +44 208 068 9665
Website: https://straitsresearch.com/

About Us:
Regardless of whether you're looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with what customers purchase. We overcome the issues of our customers by recognizing and deciphering just the target group, while simultaneously generating leads with the highest precision. We seek to collaborate with our customers to deliver a broad spectrum of results through a blend of market and business research approaches. This approach of using various research and analysis strategies enable us to determine greater insights by eliminating the research costs.

This release was published on openPR.